Synaffix BV jobs and careers
Netherlands
About Synaffix BV
Synaffix BV is a biotech company that has established a proprietary, clinical-stage antibody-drug conjugate (ADC) technology platform that delivers best-in-class ADCs (safety and efficacy). Our platform is commercially validated by well over $7.6 billion in technology out-licensing deals with partners including ADC Therapeutics, Mersana Therapeutics, Shanghai Miracogen, Innovent Biologics, ProfoundBio and Kyowa Kirin. These partnerships have rapidly translated Synaffix technology into >20 ADCs currently in development by our partners, where 5 of these have already initiated Phase 1 clinical trials. Through the platform, we can rapidly generate best-in-class ADCs for our partners from any antibody and our patent portfolio protects our proprietary processes and any resulting Products through at least 2039. Additionally, Synaffix technology is being deployed to address unmet medical need in several multi-billion-dollar, high growth market segments such as immune cell engagers and targeted gene therapy. Synaffix BV was acquired by Lonza in May 2023.
- Employees
- 11 to 50
- Headquarters
- Netherlands
Leadership
The top of Synaffix BV's org chart, with how many people report into each leader.
Peter van de Sande
CEO
30 reports
Peter Tjeerdsma
VP CMC And Regulatory
18 reports
Anthony Deboer
Head Of Business Development
8 reports
Harold Jansen
Head Of Finance
1 report
Jobs at Synaffix BV
No open positions right now. Explore more companies on TheJobsMap.